Fund moves
23 tracked managers disclosed the same change for Q3 2024. From a 13F filed Nov 14, 2024 covering holdings at Sep 30, 2024 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Dec 9, 2024 · Filed Dec 9, 2024
Biogen's Head of Development sold $17K of Biogen shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$17,293
Shares × reported transaction price
40 days after results of Oct 30, 2024, 65 days before results of Feb 12, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 23, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.
Gray v. Biogen Inc., docket 1:24-cv-12691, via CourtListener (court records). Nature of suit 850, company named as first defendant
FDA approved Skyclarys on Dec 20, 2024, 11 days after this trade.
New use approved (efficacy supplement). Active ingredient: Omaveloxolone. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −3.6% | +0.3% | −3.9% |
| 30 days | −4.8% | −3.7% | −1.1% |
| 90 days | −3.6% | −7.0% | +3.4% |
| 180 days | −14.2% | −0.5% | −13.7% |
| 365 days | +13.6% | +14.1% | −0.5% |
Past results only. Not a forecast.
Fund moves
23 tracked managers disclosed the same change for Q3 2024. From a 13F filed Nov 14, 2024 covering holdings at Sep 30, 2024 — a quarter-end snapshot, not a live trade.
Fund moves
40 tracked managers disclosed the same change for Q3 2024. From a 13F filed Nov 14, 2024 covering holdings at Sep 30, 2024 — a quarter-end snapshot, not a live trade.
Fund moves
10 tracked managers disclosed the same change for Q3 2024. From a 13F filed Nov 14, 2024 covering holdings at Sep 30, 2024 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.